Zhao Yu, Li Hong-Hua, Dou Li-Ping, Jing Yu, Wang Quan-Shun, Yu Li
Department of Hematology, PLA General Hospital, Beijing 100853, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Oct;16(5):990-2.
This study was purposed to investigate the feasibility of inhibitor of DNA banding 4 (Id4) as a reporter for acute lymphoblastic leukemia (ALL) patients before their clinical relapse. Id4 promoter at methylation status was detected by MS-PCR in bone marrow samples from the ALL patients who had been in their complete remission (CR) for 6 to 8 months with follow-up period of at least three months. The results showed that Id4 methylation were found in 20 out of all 32 patients (62.5%). The remainder 12 patients were fourd Id4 unmethylated, 1 case out of whom relapsed within the next 3-month of follow-up (8.33%), while 10 out of 20 patients (50%) with Id4 methylation relapsed within the same follow-up period. Existence of high risk factors at de novo diagnosis didn't correlated with the Id4 methylation status. In conclusion, Id4 could be regard as a reporter for ALL patients before their relapse.
本研究旨在探讨DNA结合抑制因子4（Id4）作为急性淋巴细胞白血病（ALL）患者临床复发前报告指标的可行性。采用甲基化特异性聚合酶链反应（MS-PCR）检测处于完全缓解（CR）6至8个月且随访期至少3个月的ALL患者骨髓样本中Id4启动子的甲基化状态。结果显示，32例患者中20例（62.5%）检测到Id4甲基化。其余12例患者Id4未甲基化，其中1例在接下来3个月的随访期内复发（8.33%），而20例Id4甲基化患者中有10例（50%）在同一随访期内复发。初诊时存在高危因素与Id4甲基化状态无关。总之，Id4可被视为ALL患者复发前的报告指标。
